Lantern Pharma (NASDAQ: LTRN) and its subsidiary Starlight Therapeutics have published Phase 1a clinical data for LP-184 (zirdafulven) in recurrent glioblastoma, a finding that, while not demonstrating objective tumor responses, establishes the dosing basis for a combination strategy now moving toward a mid-stage trial. The study, which enrolled 16 patients, appeared in the October 2026 issue of Cancer Research Communications and reported that LP-184 was generally well tolerated, with a recommended expansion dose of 0.39 mg/kg. The absence of radiographic responses is a limitation, but the company is emphasizing the translational insight that emerged: limited drug exposure in brain tumors, which directly informed the design of the next study.
The key implication is that Lantern plans to test LP-184 with spironolactone, an FDA-approved drug that in preclinical models reduced the concentration of LP-184 needed to kill glioblastoma cells by threefold to sixfold. That combination is slated for a Phase 1b/2a trial in patients at first recurrence of glioblastoma, sponsored by Starlight Therapeutics under an FDA-cleared Investigational New Drug application. The trial will assess safety, pharmacokinetics and objective response, and its rationale was developed with support from Lantern’s RADR artificial intelligence platform and collaborators at Johns Hopkins University. For investors, the publication provides peer-reviewed validation of the company’s approach and a clear regulatory path forward, even as it underscores the challenge of achieving therapeutic drug levels in the brain. The company’s full announcement is available through https://ibn.fm/qaLVQ, and additional information on Lantern Pharma can be found at Lantern Pharma (NASDAQ: LTRN).
The context matters because glioblastoma remains one of oncology’s most difficult targets, with few therapies extending survival after recurrence. LP-184 has received FDA Fast Track Designation for glioblastoma and triple-negative breast cancer, as well as Orphan Drug Designations for certain central nervous system cancers, signaling regulatory recognition of the unmet need. The Phase 1a data, while modest in efficacy, provide a foundation for the combination approach and highlight the role of Lantern’s AI-driven platform in shaping clinical development. The latest updates on LTRN are available in the company’s newsroom at https://ibn.fm/LTRN.
The announcement was distributed through MissionIR, a communications platform within the Dynamic Brand Portfolio at IBN. MissionIR provides services including wire distribution via InvestorWire and editorial syndication to 5,000+ outlets, which help companies like Lantern reach a broad investor audience.
